US FDA approves Inovio's treatment for rare throat disease; shares surge
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓The US FDA approved Inovio’s Voceryq to treat recurrent respiratory papillomatosis, a rare throat disease.
- ✓Shares of Inovio got a boost, rising 257% in extended trading.
- ✓CEO Jacqueline Shea said, "Physicians are primarily looking for therapies that reduce the need for surgery." The drug should be available within 60 days.
Story at a Glance
- Category
- BUSINESS
- Reported By
- Reuters
- Reading Speed
- 2 Minute(s)
- Market Focus
- India Economy
Shares of Inovio were up 257% in extended trading.
Sign up here.
Inovio's therapy INO-3107, branded as Voceryq, gives a new treatment option for patients with recurrent respiratory papillomatosis, which causes growths in the airways and often requires repeated surgeries.
Recurrent respiratory papillomatosis is characterized by recurrent wart-like growths in the throat and airways.
The condition is usually caused by HPV types 6 and 11 and can affect a person's ability to speak and breathe. Although the growths are not cancerous, they often return after treatment.
Doctors currently treat it by surgically removing the growths, but many patients require multiple procedures each year because the condition often recurs.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Reuters
Read the full, original unfiltered story directly on the publisher's portal.